ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pneumococcal 20-Valent Conjugate Vaccine

Also written as “20vPnC”, “20-valent pneumococcal conjugate vaccine” and “Prevnar 20”.

Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Respiratory Syncytial Virus Infections, led by 4 companies.

Drug pagePneumococcal 20-Valent Conjugate Vaccine: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 29, 201822 company-led studies, 5 open or runningNext primary completion: Jun 10, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer183 open or runningphase 3since Nov 29, 2018Nov 29, 2018Jun 10, 2027phase 1 · NCT07023081
GlaxoSmithKlineits history only20 open or runningphase 3since May 18, 2023Jun 3, 2022none ahead
LiteVax BVits history only11 open or runningphase 1since Mar 30, 2025Mar 30, 2025none ahead
Merckits history only11 open or runningphase 1since Dec 10, 2025Dec 10, 2025Oct 24, 2028phase 1 · NCT07300267

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 29, 2018First study: phase 3 study in Pneumococcal InfectionsFirst studyNCT03760146 · 3,902 enrolled · United States, Sweden
  2. Feb 1, 20192 phase 3 studies in Pneumococcal InfectionsNCT03828617, NCT03835975
  3. May 6, 20202 phase 3 studies in Pneumococcal InfectionsNCT04379713, NCT04382326
  4. Aug 21, 20203 phase 3 studies in Pneumococcal InfectionsNCT04546425, NCT04526574, NCT04530838
  5. Nov 18, 2020Phase 3 study in Pneumococcal InfectionsNCT04642079 · 839 enrolled · United States
  6. May 3, 20212 phase 3 studies in Pneumococcal InfectionsNCT04875533, NCT04887948
  7. Jun 1, 2022Phase 3 study in Pneumococcal InfectionsNCT05408429 · 356 enrolled · Hungary, Poland, Spain
  8. Aug 22, 2022Phase 3 study in Pneumococcal InfectionsNCT05512819 · 541 enrolled · India, Taiwan
  9. May 16, 2023Phase 3 study in Pneumococcal InfectionsNCT05875727 · 405 enrolled · India
  10. Jun 5, 20252 phase 1 studies in Pneumococcal InfectionsNCT07019909, NCT07023081
  11. Aug 14, 2025Phase 3 study in HealthyNCT07160244 · 6,000 planned · United States, Argentina, Brazil and more
  12. Jul 24, 2026Phase 3 study in Pneumococcal InfectionsNCT07754539 · 1,250 planned · China

Ahead

  1. Jun 10, 2027Primary completion: phase 1 study in Pneumococcal InfectionsNCT07023081
  2. Nov 6, 2028Primary completion: phase 3 study in HealthyNCT07160244
  3. Nov 30, 2028Primary completion: phase 3 study in Pneumococcal InfectionsNCT07754539

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A pneumococcal conjugate vaccine containing 20 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 20-Valent Conjugate Vaccine”name, by rule

Studies

All 18 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07754539Pneumococcal Infections · China3RecruitingNov 30, 20281,250
NCT07160244Healthy · United States, Argentina, Brazil and more3RecruitingNov 6, 20286,000
NCT07023081Pneumococcal Infections · China1Active, not recruitingJun 10, 2027200
NCT07019909Pneumococcal Infections · China1CompletedJan 28, 2026400
NCT05875727Pneumococcal Infections · India3CompletedOct 2, 2023405
NCT05512819Pneumococcal Infections · India, Taiwan3CompletedSep 20, 2025541
NCT05408429Pneumococcal Infections · Hungary, Poland, Spain3CompletedJun 1, 2023356
NCT04887948Pneumococcal Infections · United States3CompletedDec 8, 2021570
NCT04875533Pneumococcal Infections · Japan, Korea, Republic of, Taiwan3CompletedMay 13, 20221,425
NCT04642079Pneumococcal Infections · United States3CompletedApr 6, 2022839
NCT04530838Pneumococcal Infections · Japan3CompletedApr 2, 2022668
NCT04546425Pneumococcal Infections · Australia, Belgium, Czechia and more3CompletedApr 22, 20221,258
NCT04526574Pneumococcal Infections · United States3CompletedJun 29, 20211,796
NCT04382326Pneumococcal Infections · United States, Puerto Rico3CompletedSep 2, 20221,997
NCT04379713Pneumococcal Infections · United States, Argentina, Canada and more3CompletedAug 31, 20221,511
NCT03835975Pneumococcal Infections · United States, Sweden3CompletedFeb 12, 2020875
NCT03828617Pneumococcal Infections · United States3CompletedOct 9, 20191,710
NCT03760146Pneumococcal Infections · United States, Sweden3CompletedDec 16, 20193,902

How it is read

Names in the registry

  • “20vPnC”, 10 entries
  • “20-valent pneumococcal conjugate vaccine”, 7 entries
  • “Prevnar 20”, 2 entries
  • “PCV20 (Stage 1)”, 1 entry
  • “PCV20 (Stage 2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.